Dispatches from the FT Global Healthcare and biotech conference
Big Pharma
Big Pharma: “For these customers, classical manufacture is only part of a core strategy during critical phases of prod lifecycle. The main constraints to further outsource manufacturing activities are partially heavy internal over-capacities and the issues related to the downsizing of those capacities. The investment focus is on specialised techs and biotech especially in emerging markets such as China.”